SAINT PAUL, Minn.--(BUSINESS WIRE)--Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary ...
A new clinical classification system is presented to define the severity of an acute pulmonary embolism (PE) and assist in developing adult treatment strategies in a clinical practice guideline issued ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...
- Data presented show maintained or improved responses in multiple efficacy endpoints among patients treated with sotatercept plus stable background therapy for up to 48 weeks - - Patients receiving ...
Your circulatory system works all day, every day, to pump oxygen throughout your body. There are cardiovascular conditions that can impact this system. Your circulatory system, also known as your ...
– Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 – – Presentation of echocardiography data from the PULSAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results